LY30410 (rivastigmine)

LY30410 is a multi-day transdermal patch formulation of rivastigmine, developed by Luye Pharma Group using its proprietary Novel Drug Delivery System (NDDS). Rivastigmine is a carbamate derivative that acts as a reversible, dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). By inhibiting these enzymes, it prevents the breakdown of acetylcholine, thereby increasing its concentration in the brain and improving cholinergic function in patients with Alzheimer's dementia. Unlike the conventional once-daily patches, LY30410 is designed for twice-weekly administration, which aims to enhance patient adherence and provide more stable plasma concentrations of the drug. It has received marketing authorization in several European countries for the treatment of mild to moderate Alzheimer's disease.

Other names

Rivastigmine Multi-Day Transdermal PatchRivastigmine MD Patchtwice-weekly rivastigmine patch